Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3501-3508

  Qin, Shukui ^a   Bai, Yuxian ^b   Lim, Ho Yeong ^f   Thongprasert, Sumitra ⁱ   Chao, Yee ^k   Fan, Jia ^c   Yang, Tsai Shen ^l   Bhudhisawasdi, Vajarabhongsa ^j   Kang, Won Ki ^f,g   Zhou, Yu ^d   Lee, Jee Hyun ^h   Sun, Yan ^e  

^a Nanjing Bayi Hospital   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d R D   (China)

^e CANCER HOSPITAL   (China)

^f Samsung Medical Center   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Sanofi Korea   (South Korea)

ⁱ CHIANG MAI UNIVERSITY   (Thailand)

^j KHON KAEN UNIVERSITY   (Thailand)

^k TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^l CHANG GUNG UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOEMBOLIZATION; CHINA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KOREA; LEUKOPENIA; LIVER CELL CARCINOMA; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; TAIWAN; THAILAND; THROMBOCYTOPENIA; VOMITING; ADOLESCENT; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPARATIVE STUDY; INTERNATIONAL COOPERATION; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84891587587     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.5643     Document Type: Article

References (32)

1. Yuen MF, Hou JL, Chutaputti A: Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol 24:346-353, 2009
2. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
3. Yang T, Lu JH, Wu MC: Hepatocellular carcinoma in China. Student BMJ 18:c1026, 2010
4. Chow PK, Tai BC, Tan CK, et al: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 36:1221-1226, 2002
5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 10:25-34, 2009
6. Zhu AX: Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist 11:790-800, 2006
7. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
8. Nowak AK, Chow PK, Findlay M: Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 40:1474-1484, 2004
9. Thomas MB, Zhu AX: Hepatocellular carcinoma: The need for progress. J Clin Oncol 23:2892-2899, 2005
10. Yen Y, Lim DW, Chung V, et al: Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: A California Cancer Consortium Trial. Am J Clin Oncol 31: 317-322, 2008
11. Louafi S, Boige V, Ducreux M, et al: Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study. Cancer 109:1384-1390, 2007
12. Qin S, Wang YJ, Wu Q, et al: Phase II study of oxaliplatin + 5-fluorouracil/leucovorin in patients with unresectable hepatocellular carcinoma. Presented at the ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21, 2007 (abstr 151)
13. Qin SK, Cao MR, Qian J, et al: Clinical study of FOLFOX regimen for the patients with advanced hepatocellular carcinoma [in Chinese]. Chin Clin Oncol 10:58-60, 2005
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Fuse N, Doi T, Ohtsu A, et al: Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. Jpn J Clin Oncol 37: 434-439, 2007
16. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091, 2006
17. Patt YZ, Charnsangavej C, Yoffe B, et al: Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12: 1204-1211, 1994
18. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 362:1907-1917, 2003
19. Rampone B, Schiavone B, Martino A, et al: Current management strategy of hepatocellular carcinoma. World J Gastroenterol 15:3210-3216, 2009
20. Yeo W, Mok TS, Zee B, et al: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538, 2005
21. Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 304:2154-2160, 2010
22. Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: Two ends of the therapeutic spectrum. Lancet Oncol 5:409-418, 2004
23. Lai CL, Wu PC, Chan GC, et al: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: A prospective randomized trial. Cancer 62:479-483, 1988
24. Hsu C, Shen YC, Cheng CC, et al: Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemp Clin Trials 31:55-61, 2010
25. Lee S, Yoon S, Shin S, et al: Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: A retrospective, singleinstitution study. Presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 20-22, 2011 (abstr 339)
26. Yau T, Chan P, Ng KK, et al: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response. Cancer 115:428-436, 2009
27. Lee HC: Systemic chemotherapy of hepatocellular carcinoma: Korean experience. Oncology 75:114-118, 2008 (suppl 1)
28. Chen PJ, Furuse J, Han KH, et al: Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts' opinion. Liver Int 30:1427-1438, 2010
29. Cheng A, Kang Y, Lin D, et al: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 29: 2011 (suppl; abstr 4000)
30. Yau TCP, Cheung FY, Lee AS, et al: Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. Presented at the Joint ECCO 15 and 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009
31. Je Y, Schutz FA, Choueiri TK: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974, 2009
32. Chinese Ministry of Health: Diagnosis and Treatment Guideline of Primary Liver Cancer (ed 2011). Beijing, China, Chinese Ministry of Health, September 30, 2011